Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,910 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostatic Cancer Clear all
Completed Not applicable Interventional

Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.

NCT01964638
View directory record Official record
Conditions
Prostate Cancer
Interventions
Targeted Biopsy
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Not applicable Interventional

PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care Intervention

NCT05755490
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
PROWESS
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Not applicable Interventional Results available

Performance Evaluation of the AMS CONTINUUM™ Device

NCT00894933
View directory record Official record
Conditions
Prostate Cancer
Interventions
CONTINUUM™
Device
Lead sponsor
American Medical Systems
Industry
Eligibility
40 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Burlington, Massachusetts • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 22, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy

NCT02420652
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Aspirin, Laboratory Biomarker Analysis, Metformin Hydrochloride, Placebo
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 22, 2026, 10:34 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

NCT02526368
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Hyperpolarized 13C-Pyruvate, Hyperpolarized 13C,15N2-urea, Magnetic Resonance Spectroscopic Imaging
Drug · Procedure
Lead sponsor
Ivan de Kouchkovsky, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 22, 2026, 10:34 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

PSMA PET Combined With MRI for the Detection of PCa

NCT07052214
View directory record Official record
Conditions
PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET, Diagnostic Imaging, Elevated PSA, Positron Emission Tomography, Prostate Biopsy, Carcinoma of the Prostate
Interventions
68Ga-PSMA-11
Drug
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer

NCT00828308
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ixabepilone, Prostatectomy
Drug · Procedure
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma

NCT03427476
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
CTT1057
Drug
Lead sponsor
Cancer Targeted Technology
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

NCT01535040
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Tobacco Use Disorder
Interventions
memantine hydrochloride, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 22, 2026, 10:34 PM EDT
Recruiting Phase 1 Interventional

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT07219147
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET Scan, Sipuleucel-T
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

NCT02933255
View directory record Official record
Conditions
Prostate Cancer
Interventions
PROSTVAC-V/F, Nivolumab, Prostatectomy, Biopsy, Tylenol
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 22, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

NCT03999515
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Enzalutamide, Erdafitinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

NCT00538668
View directory record Official record
Conditions
Prostate Cancer
Interventions
117Lu-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 85 Years · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

NCT02218606
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate 1000 mg po daily, Cabazitaxel 25 mg/m2 IV, prednisone 5 mg po BID
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
4
States / cities
New York, New York • Philadelphia, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 22, 2026, 10:34 PM EDT
Recruiting Not applicable Interventional

Multilevel Intervention for Precision Oncology

NCT06825715
View directory record Official record
Conditions
Advanced Cancers of the Prostate, Cancers of the Lung
Interventions
Multilevel intervention
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
2,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Not applicable Interventional

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

NCT02080689
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher
Other
Lead sponsor
GenomeDx Biosciences Corp
Industry
Eligibility
Male only
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
19
States / cities
Anchorage, Alaska • Los Angeles, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 22, 2026, 10:34 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

NCT01777217
View directory record Official record
Conditions
Over-Active Bladder
Interventions
Solifenacin succinate, Placebo
Drug
Lead sponsor
Advanced Research Network
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Not applicable Interventional

Prostate Cancer: Family Care for Patients and Spouses

NCT00708968
View directory record Official record
Conditions
Prostate Cancer, Quality of Life, Cancer Survivorship
Interventions
FOCUS Program
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Oct 22, 2026, 10:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

NCT04633252
View directory record Official record
Conditions
Cancer Of Prostate, Prostate Neoplasms
Interventions
PDS01ADC, Docetaxel, M7824, Prednisone, ADT
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 10:34 PM EDT
Terminated Phase 1 Interventional Results available

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

NCT00976508
View directory record Official record
Conditions
Colorectal Neoplasms, Lung Neoplasms, Breast Neoplasms, Prostatic Neoplasms, Sarcoma
Interventions
figitumumab, pegvisomant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 22, 2026, 10:34 PM EDT
Active, not recruiting Phase 3 Interventional

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

NCT03582774
View directory record Official record
Conditions
Recurrent Prostate Carcinoma
Interventions
Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
Other · Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT02159950
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Sipuleucel-T, Tasquinimod
Other · Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 22, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy

NCT01144897
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer, Prostate Cancer
Interventions
PET Acetate scan, Carbon-11 labeled Acetate
Radiation · Drug
Lead sponsor
Daniel Vaena
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 22, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

NCT01200810
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
placebo, gamma-secretase/Notch signalling pathway inhibitor RO4929097, bicalutamide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 22, 2026, 10:34 PM EDT